Loading stock data…
Loading stock data…
US$4.67
Get one email when ANTX crosses your level. Checked every 15 minutes during market hours.
▲ +0.00 (0.00%)up today
USD · data via Finnhub · delayed/cached up to 1–5 min
Get an AI-written, balanced deep-dive — performance, valuation, technicals, and the bull vs. bear case. Sign in to get started.
RSI (14-day)
51.1
NeutralAbove 70 can signal overbought; below 30, oversold.
MACD
0.01
Bearish momentumMACD below its signal line (0.03).
50-day average
4.59
Price aboveShort-term trend reference.
200-day average
2.60
Price aboveLong-term trend reference.
Daily values · indicators are descriptive, not trading advice
Healthcare · Biotechnology
AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its proprietary boron chemistry platform. The company advances treatments for serious infectious diseases with high unmet needs, including non-tuberculous mycobacterial lung disease, acute melioidosis, chronic Chagas disease, and M. abscessus lung disease. Its lead candidate, epetraborole, is an oral therapy in phase 3 clinical trials for non-t…
www.an2therapeutics.com3 strong buy · 3 buy · 1 hold · 0 sell · 0 strong sell (7 analysts, 2026-07-01)
3 strong buy · 3 buy · 1 hold · 0 sell · 0 strong sell (7 analysts, 2026-06-01)
0 strong buy · 0 buy · 3 hold · 1 sell · 2 strong sell (6 analysts, 2026-05-01)
0 strong buy · 0 buy · 3 hold · 1 sell · 2 strong sell (6 analysts, 2026-04-01)
| Quarter | Estimate | Actual | Result |
|---|---|---|---|
| 2026-05-11 | -0.23 | -0.29 | ✗ Miss |
| 2026-03-17 | -0.24 | -0.29 | ✗ Miss |
| 2026-02-17 | 0.6 | 0.69 | ✓ Beat |
| 2026-01-29 | 6.45 | 6.57 | ✓ Beat |
| 2025-11-12 | -0.22 | -0.31 | ✗ Miss |
| 2025-09-16 | 0.82 | 0.86 | ✓ Beat |
| 2025-08-12 | -0.31 | -0.21 | ✓ Beat |
Companies in the same industry, via Finnhub